ESG Challenges in Pharma
India is the world's largest supplier of generic medicines and a major exporter of Active Pharmaceutical Ingredients (APIs). But the pharmaceutical manufacturing process carries a significant environmental footprint that regulators, investors, and global buyers can no longer ignore.
API manufacturing is energy- and solvent-intensive. Chemical synthesis requires high-temperature reactions, steam generation, and continuous process heating — all of which drive substantial Scope 1 emissions. Solvent recovery, distillation, and drying processes consume large volumes of energy, while fugitive emissions from reactors and storage tanks add to the facility's GHG inventory.
Hazardous waste from chemical synthesis — including spent solvents, heavy metal residues, and reaction by-products — must be managed under strict CPCB regulations. Effluent treatment is another critical challenge: pharma wastewater contains complex organic compounds and antimicrobial residues that require advanced treatment before discharge.
On the demand side, European pharmaceutical buyers are now requiring supply chain ESG data under the EU CSRD. Indian API exporters who cannot provide audited carbon footprint data, environmental compliance records, and social responsibility disclosures risk losing contracts with multinational pharma companies. Meanwhile, SEBI's mandatory BRSR reporting applies to all listed pharma companies in India.
Our Services
-
Carbon Audit — Process & Energy
Facility-level Scope 1, 2, and 3 carbon audits using the GHG Protocol. We map emissions from boilers, steam systems, solvent recovery units, diesel generators, refrigeration, and purchased electricity — giving you a complete picture of your manufacturing carbon footprint. Learn more
-
BRSR Reporting & SEBI Compliance
End-to-end support for BRSR filings tailored to the pharmaceutical sector. We help you collect environmental data (emissions, waste, water), social metrics (workforce safety, community impact), and governance disclosures aligned with SEBI's framework. What is BRSR?
-
CSRD Compliance for EU Pharma Supply Chains
Indian API manufacturers and contract research organisations supplying European pharmaceutical companies need CSRD-ready ESG data. We build reporting infrastructure covering carbon emissions, water stewardship, waste management, and labour practices — so you stay in your buyers' qualified supplier lists. CSRD guide for Indian exporters
-
Environmental Compliance & CPCB
Regulatory compliance support for Central Pollution Control Board (CPCB) and State Pollution Control Board (SPCB) requirements — including consent to operate, environmental clearances, emission monitoring, and effluent discharge standards for pharma manufacturing units.
-
Hazardous Waste Management
Assessment and strategy for managing pharmaceutical hazardous waste streams — spent solvents, chemical residues, expired products, and biomedical waste. We help you implement compliant disposal, recycling, and solvent recovery programmes that reduce both environmental impact and operating costs.
-
Net Zero Roadmap
A phased, science-backed plan to reach net-zero emissions for pharma operations — covering energy efficiency in process heating, renewable energy procurement, steam optimisation, supply chain engagement, and verified carbon offsets. Net zero vs. carbon neutral
Where We Serve Pharma
Gujarat is India's largest pharmaceutical manufacturing hub, accounting for over 30% of the country's pharma output. We serve pharma companies across the state's key production corridors.
Frameworks We Work With
We align your pharma ESG strategy with the frameworks that matter most to your regulators, investors, and global supply chain partners.
Frequently Asked Questions
India's pharma sector faces significant ESG challenges including high energy consumption in API manufacturing, solvent-intensive chemical synthesis generating hazardous waste, effluent treatment and water pollution, high Scope 1 emissions from boilers and process heating, and increasing pressure from EU pharmaceutical buyers demanding supply chain ESG data under CSRD.
Yes. SEBI has mandated BRSR for the top 1,000 listed companies by market capitalization. Many large pharmaceutical companies listed on NSE or BSE fall within this threshold and must file BRSR disclosures annually, covering environmental, social, and governance metrics specific to their operations.
The EU CSRD requires large EU companies to report on their full value chain, including non-EU suppliers. Indian API manufacturers supplying European pharma companies will need to provide detailed ESG data — covering carbon emissions, water usage, waste management, and labour practices — to remain in their buyers' supply chains.
In pharma manufacturing, Scope 1 emissions primarily come from on-site boilers and steam generation, process heating and cooling systems, solvent recovery and incineration units, diesel generators for backup power, and fugitive emissions from chemical reactors and storage tanks. A comprehensive carbon audit maps each source and quantifies its contribution.
Start your pharma ESG journey
Talk to our team about carbon audits, BRSR compliance, and sustainability strategy for pharmaceutical operations.
Get in Touch